Medical experts provide an overview of the signs and symptoms of pneumococcal infections.

Key opinion leaders discuss factors leading to the development of novel pneumococcal vaccines.

High-risk patient populations for pneumococcal pneumonia are discussed by Christina Madison, PharmD, FCCP, AAHIVP.

William Schaffner, MD, and Christina Madison, PharmD, FCCP, AAHIVP provide an overview of the identification and differential diagnosis of pneumococcal pneumonia.

Mary Bridgeman, PharmD, BCPS, BCGP, FASCP, drives a discussion around preventative measures to limit the spread of pneumococcal infection.

Dr. Bridgeman highlights approved pneumococcal vaccines and their indications.

Secondary pneumococcal vaccine schedules are explored by Drs Schaffner, Bridgeman, and Madison.

The panelists discuss the evolution of the pneumococcal vaccine landscape.

Medical experts discuss clinical, social, and economic obstacles limiting pneumococcal vaccination efforts.

The significance of engaging patients and providing key educational points regarding pneumococcal vaccines is highlighted.

Christina Madison, PharmD, FCCP, AAHIVP, discusses disparities in patient populations directly influencing limited access to appropriate treatment and preventative care.

Dr Schaffner underscores the significance of multidisciplinary teams in the effort to optimize vaccination rates for pneumococcal disease.

Cost considerations for the rollout of new pneumococcal vaccines are discussed by a panel of medical experts.